| Literature DB >> 35659714 |
David N Naumann1, Rahul K Hejmadi2, Jonathan J R Richardson3.
Abstract
BACKGROUND: Prostate cancer may rarely metastasize to the colon and colonic lymph nodes, and local treatment of oligometastatic deposits may improve oncological outcomes. Immunohistochemical stains are used to determine the most likely source of metastatic deposits when they are seen within surgical specimens. The aim of this case report is to illustrate how such techniques were used to identify unexpected prostatic metastases within the pericolic fat of a sigmoid colon resection specimen following elective curative surgery for colorectal cancer. To our knowledge, this is the first report of complete excision of oligometastatic deposits of prostate cancer found incidentally within the specimen of another cancer. CASE REPORT: An 89-year-old Caucasian man underwent sigmoid colectomy for an obstructing colorectal cancer in the sigmoid colon with some mesenteric lymphadenopathy. He had previously received radical radiotherapy for prostate cancer 10 years earlier. When the specimen was examined by the histopathologist, it was noted that the pericolic fat adjacent to the colorectal adenocarcinoma contained some metastatic deposits. Positive immunohistochemical staining for prostate-specific antigen and prostate-specific acid phosphatase with negative staining for CDX2 and CK20 revealed these to be prostatic metastases rather than colonic. Since these were completely excised, and there were no other metastases, this represented a serendipitous, curative excision of oligometastatic deposits of an additional cancer to the one that was being treated.Entities:
Keywords: Colorectal cancer; Colorectal resection; Lymph nodes; Metastases; Prostate cancer
Mesh:
Year: 2022 PMID: 35659714 PMCID: PMC9167515 DOI: 10.1186/s13256-022-03441-4
Source DB: PubMed Journal: J Med Case Rep ISSN: 1752-1947
Fig. 1Histopathology from the colonic specimen depicting A mucinous colonic adenocarcinoma in mesenteric fat, B nodal metastases (mucinous colonic adenocarcinoma), C, D deposits of metastatic prostate adenocarcinoma, E PSA immunohistochemistry positive confirming prostate adenocarcinoma metastases, F PSAP immunohistochemistry positive confirming prostate adenocarcinoma metastases, G CDX2 immunohistochemistry negative, excluding gastrointestinal tract metastases, and H CK20 immunohistochemistry, very focally positive, excluding a gastrointestinal tract primary